GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.

and independent laboratories shows that one ranitidine 300 mg tablet can contain tens of thousands of nanograms (ng) of NDMA, greatly exceeding the FDA’s daily acceptable intake limit of 96 ng ...

Apotex also said it was recalling ranitidine tablets in the US. The BBC has approached GlaxoSmithKline - original makers of Zantac. The company is reported to have stopped distributing its generic ...

The four being recalled are Zantac 150mg/10ml Syrup, Zantac 50mg/2ml Injection, Zantac 150mg Tablets and Zantac 300mg Tablets. But patients should keep taking their prescribed medicine ...

The first lawsuit claiming that gastrointestinal drug Zantac causes cancer has been voluntarily dismissed a week before it was due to come to trial, in an early victory for the pharma companies ...

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

Learn more› By Roderick Scott and Ryan Whitwam After a new round of testing, we’ve added the 2024 Amazon Fire HD 8 tablet as our budget pick and added Samsung’s Galaxy Tab S10+ to the ...

How do you explain one Zantac manufacturer kiboshing a favorable trend of defense verdicts and decisions – with a massive $2.2 billion settlement? The answer appears to lie with the whistleblower suit ...

The cool part is – thanks to his instructions, you can build one yourself! This tablet sports a FullHD touchscreen IPS display and shows some well-thought-out component mounting, using heat-set ...

Learn more› By Roderick Scott, Dave Gershgorn and Nick Guy Apple just announced its new $500 iPad mini tablet. We plan to test it soon, and you can read more details in our What to look forward ...